Applying PCSK9 Inhibitors to Optimize Outcomes in Patients with Dyslipidemia
TARGET AUDIENCE
EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants will be better able to do the following:
- Identify the current dyslipidemia guidelines and consensus statements to achieve LDL-C goal
- Compare available pharmacotherapies that reduce LDL-C
- Analyze the details of the CVD outcomes trial data for patients on PCSK9 inhibitors, including the diabetic patient subset
- Prioritize the most current treatment plans for patients with familial hypercholesterolemia
- Apply current algorithms and treatment models for managing the high-risk patient with dyslipidemia
FACULTY
![]() | Christopher P. Cannon, MD (Program Chair) |
Christie M. Ballantyne, MD Professor of Medicine Vice-Chair of Research-Department of Medicine Chief-Section of Cardiology Chief-Section of Cardiovascular Research Baylor College of Medicine Houston, Texas | |
![]() | Alan S. Brown, MD Director, Division of Cardiology Advocate Lutheran General Hospital President-Elect, National Lipid Association Co-Director, Cardiology Service Line Advocate Medical Group Clinical Associate Professor Loyola Stritch Medical School Park Ridge, Illinois |
![]() | Robert H. Eckel, MD Professor of Medicine Division of Endocrinology, Metabolism, and Diabetes, and Cardiology Charles A. Boettcher II Chair in Atherosclerosis University of Colorado Anschutz Medical Campus Aurora, Colorado |
![]() | Robert P. Giugliano, MD, SM Associate Professor of Medicine Harvard Medical School Senior Investigator, TIMI Study Group Cardiovascular Division Brigham and Women's Hospital Boston, Massachusetts |
James A. Underberg, MD, MS Clinical Assistant Professor of Medicine NYU School of Medicine NYU Center for Prevention of Cardiovascular Disease Director Bellevue Hospital Lipid Clinic President-Elect National Lipid Association New York, New York |
Disclosure of Conflicts of Interest
Faculty | Relationship Identified With: |
Christopher P. Cannon, MD | Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; Amgen Inc.; Amarin Corporation; Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eisai Co., Ltd.; GlaxoSmithKline Plc; Kowa; LipoMedix; Merck & Co., Inc.; Pfizer Inc.; Regeneron; Sanofi; Takeda Pharmaceuticals U.S.A., Inc. Grant/Research Support: Amgen Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Company Limited; Janssen Global Services, LLC; Merck & Co., Inc.; Takeda Pharmaceuticals U.S.A., Inc. |
Christie M. Ballantyne, MD | Consultant/Advisor: Abbott Diagnostics; Amarin Corporation; Amgen Inc.; AstraZeneca; Boehringer Ingelheim; Eli Lilly and Company; Ionis Pharmaceuticals, Inc.; Matinas BioPharma Holdings Inc.; Merck & Co., Inc.; Novartis Global; Pfizer Inc.; Regeneron; Roche Diagnostics; Sanofi Grant/Research Support: Abbott Diagnostics; Amarin Corporation; Amgen Inc.; Esperion; Ionis Pharmaceuticals, Inc.; Novartis Global; Pfizer Inc.; Regeneron; Roche Diagnostics; Sanofi |
Alan S. Brown, MD | Consultant/Advisor: Akcea Therapeutics; Amgen Inc.; Kastle Therapeutics; Kowa; Merck & Co., Inc.; Regeneron Speaker's Bureau: Amgen Inc.; Kowa; Regeneron; Sanofi |
Robert H. Eckel, MD | Consultant/Advisor: Regeneron; Sanofi |
Robert P. Giugliano, MD, SM | Consultant/Advisor: Amarin Corporation; Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVS Caremark; Daiichi Sankyo Company Limited; GlaxoSmithKline Plc; Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Portola Pharmaceuticals, Inc.; Pfizer Inc.; Stealth BioTherapeutics Incorporated Grant/Research Support: Amgen Inc. Speakers Bureau: Amgen Inc.; Daiichi Sankyo Company Limited; Merck & Co., Inc. |
James A. Underberg, MD, MS | Consultant/Advisor: Gilead; Proteostasis Therapeutics, Inc.; Vertex Pharmaceuticals Incorporated Consultant/Advisor: Aegerion Pharmaceuticals Inc; Akcea Therapeutics; Alexion Pharmaceuticals; Amarin Corporation; Amgen Inc.; Invitae Corporation; Regeneron; Sanofi Grant/Research Support: Aegerion Pharmaceuticals Inc; Pfizer Inc. Speakers Bureau: Alexion Pharmaceuticals; Amarin Corporation; Amgen Inc.; Regeneron; Sanofi; True Health Group LLC |
Non-faculty: Timothy Hayes, MD, PhD; Emma Boring, Nicole Brestowski and Chelsey Benedek hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
Financial Support
This activity has been supported by an independent educational grant from Amgen Inc.
Provider Information
This activity is provided by AcademicCME.
Credit Designation Statement
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact please contact admin@academiccme.com or 610.687.3300.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.50 AMA PRA Category 1 Credit(s)™
- 1.50 Non-physician